Murae Organisor

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE060601031
  • NSEID:
  • BSEID: 542724
INR
0.27
0.00 (0.00%)
BSENSE

Dec 04

BSE+NSE Vol: 24902025

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.49 cr (-13.52%) Volume

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

0.00%

Who are the top shareholders of the Murae Organisor?

06-Jun-2025

The top shareholders of Murae Organisor include individual investors with 60.02% of the shares, while Ifl Enterprises Limited holds 7.34%. Auxilia Pharmaceuticals Private Limited is the promoter with a reported stake of 0.0%, and there are no institutional holdings.

The top shareholders of Murae Organisor include individual investors, who hold a significant 60.02% of the shares. The highest public shareholder is Ifl Enterprises Limited, with a holding of 7.34%. Additionally, Auxilia Pharmaceuticals Private Limited is noted as the promoter with the highest holding, although their stake is listed as 0.0%. There are no institutional holdings from mutual funds or foreign institutional investors.

Read More

how big is Murae Organisor?

06-Jun-2025

As of Jun 06, Murae Organisor Ltd has a market capitalization of 208.20 Cr, classifying it as a Micro Cap company, with recent net sales of 854.82 Cr and a net profit of 7.52 Cr. The standalone balance sheet shows shareholder's funds of 55.85 Cr and total assets of 119.86 Cr.

Market Cap: As of Jun 06, Murae Organisor Ltd has a market capitalization of 208.20 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Murae Organisor reported Net Sales of 854.82 Cr and a Net Profit of 7.52 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Standalone balance sheet for the reporting period ending in Mar'24 shows Shareholder's Funds of 55.85 Cr and Total Assets of 119.86 Cr.

Read More

What is the bonus history of the Murae Organisor?

06-Jun-2025

Murae Organisor issued a 1:1 bonus on August 9, 2021, with a record date of August 10, 2021, meaning shareholders received an additional share for each share owned as of that date.

Murae Organisor has a bonus history that includes a 1:1 bonus issue announced on August 9, 2021. The record date for this bonus was August 10, 2021. This means that shareholders received an additional share for every share they owned as of the record date. If you have any more questions about the company or its financials, feel free to ask!

Read More

Has Murae Organisor declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Murae Organisor?

03-Jun-2025

Murae Organisor's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Krebs Biochem, Auro Labs, Bal Pharma, Amwill, and Aarey Drugs. Murae Organisor has below average management and capital structure risks, with a 1-year return of 27.92%, compared to Divi's Lab's highest return of 51.96% and Bal Pharma's lowest at -13.63%.

Peers: The peers of Murae Organisor are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Krebs Biochem, Auro Labs., Bal Pharma, Amwill, and Aarey Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Auro Labs., and Amwill, while Good management risk is found at Divi's Lab., Torrent Pharma, and Bal Pharma. Below Average management risk is noted for Murae Organisor, and Average management risk is present at Aarey Drugs. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Murae Organisor, while Below Average growth is seen at Divi's Lab. and Torrent Pharma. Good growth is noted at Bal Pharma and Amwill, and the rest have varying growth ratings. Excellent capital structure is found at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Auro Labs., while Good capital structure is noted at Torrent Pharma and Amwill. Below Average capital structure is observed at Murae Organisor and Bal Pharma, and Krebs Biochem does not qualify.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Bal Pharma has the lowest at -13.63%. Murae Organisor's 1-year return is 27.92%, which is significantly higher than Bal Pharma's but lower than Divi's Lab.'s. Additionally, Krebs Biochem and Amwill have negative six-month returns.

Read More

What is the technical trend for Murae Organisor?

09-Jun-2025

As of June 2, 2025, Murae Organisor's technical trend is mildly bullish, supported by positive weekly and monthly MACD and Bollinger Bands, despite some short-term bearish signals from daily moving averages and mixed KST indicators.

As of 2 June 2025, the technical trend for Murae Organisor has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive sentiment, while the monthly MACD is mildly bullish. Bollinger Bands are bullish on both weekly and monthly time frames, indicating upward price momentum. The Dow Theory also reflects a mildly bullish stance on both weekly and monthly charts. However, the daily moving averages are mildly bearish, which suggests some short-term weakness. The KST shows a bearish signal on the weekly but is bullish on the monthly, indicating mixed signals across time frames. Overall, the current technical stance is mildly bullish, driven primarily by the positive MACD and Bollinger Bands on the weekly and monthly charts.

Read More

Who are in the management team of Murae Organisor?

16-Jul-2025

As of March 2021, the management team of Murae Organisor includes Bhumishth Narendrabhai Patel as Chairman & Managing Director, Payal Bhumishth Patel as Whole Time Director & CFO, and several independent and additional directors, along with a Company Secretary.

As of March 2021, the management team of Murae Organisor includes the following individuals:<BR><BR>1. Bhumishth Narendrabhai Patel - Chairman & Managing Director<BR>2. Bhumishth Narendrabhai Patel - Non Executive Director<BR>3. Payal Bhumishth Patel - Whole Time Director & CFO<BR>4. Bhavik Shantilal Patel - Independent Director<BR>5. Dahyabhai Mafatlal Patel - Additional Non-Executive Director<BR>6. Parimal S Patwa - Additional Independent Director<BR>7. Harsh M Kothari - Additional Independent Director<BR>8. Madhuri Mistry - Company Secretary & Compliance Officer<BR>9. Sumitkumar Patel - Independent Director<BR>10. Premaram Patel - Additional Director<BR>11. Sanjaykumar Nai - Additional Director<BR>12. Vijaykumar Patel - Additional Director<BR><BR>This team comprises a mix of executive, independent, and additional directors, along with a compliance officer.

Read More

What does Murae Organisor do?

17-Jul-2025

Murae Organisor Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 5,155 Cr and a net profit of 28 Cr for the quarter ending March 2025. Originally founded as Earum Pharmaceuticals in 2012, it became a public company in 2019.

Overview:<BR>Murae Organisor Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Murae Organisor Ltd was originally incorporated as "Earum Pharmaceuticals Private Limited" in 2012. The company transitioned to a Public Limited status and changed its name to "Earum Pharmaceuticals Limited" in January 2019. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 5,155 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 28 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 180 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 24.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.21 <BR>Return on Equity: 13.47% <BR>Price to Book: 3.40 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Murae Organisor overvalued or undervalued?

18-Aug-2025

As of August 14, 2025, Murae Organisor is considered undervalued with a PE Ratio of 16.86 and an EV to EBIT of 11.47, making it an attractive investment opportunity despite a year-to-date stock performance of -70.05% compared to the Sensex's 3.15%.

As of 14 August 2025, Murae Organisor has moved from a grade of risky to very attractive, indicating a significant improvement in its valuation outlook. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE Ratio of 16.86, an EV to EBIT of 11.47, and a PEG Ratio of 0.01, which suggests that the stock is trading at a low valuation relative to its growth potential.<BR><BR>In comparison to its peers, Murae Organisor stands out with a much lower PE Ratio than Sun Pharma (34.24) and Divi's Lab (70.57), both of which are classified as expensive. Additionally, Murae's EV to EBITDA ratio of 11.47 is more favorable than many competitors, reinforcing its undervaluation status. Despite recent poor stock performance against the Sensex, with a year-to-date return of -70.05% compared to the Sensex's 3.15%, the valuation metrics suggest that Murae Organisor presents a compelling investment opportunity at its current price.

Read More

When is the next results date for Murae Organisor?

19-Aug-2025

Murae Organisor will declare its results on 22 August 2025.

Murae Organisor will declare its results on 22 August 2025.

Read More

Are Murae Organisor latest results good or bad?

23-Aug-2025

Murae Organisor's latest results show strong net sales growth of over 225,000% and a 296% increase in Profit After Tax, indicating improved profitability. However, a 62.5% decline in Profit Before Tax raises concerns about sustainability, leading to a current stock rating of 'Hold'.

Murae Organisor's latest results present a mixed picture. On one hand, the company has reported a remarkable increase in net sales, reaching Rs 519.52 crore, which reflects an extraordinary year-on-year growth of over 225,000%. This indicates strong market performance and suggests that the company is successfully expanding its sales.<BR><BR>Additionally, the Profit After Tax (PAT) of Rs 7.44 crore represents a substantial increase of nearly 296% compared to the average PAT of the previous four quarters. This is the highest PAT recorded in the last five quarters, indicating a positive trend in profitability and improved earnings for shareholders, as reflected in the Earnings per Share (EPS) of Rs 0.07.<BR><BR>However, there are notable concerns regarding the Profit Before Tax (PBT), which has decreased by 62.5% from the previous average, falling to Rs 0.94 crore. A significant portion of this PBT is attributed to non-operating income, which raises questions about the sustainability of the company’s core business operations. <BR><BR>Overall, while Murae Organisor shows strong sales growth and improved profitability metrics, the decline in PBT and reliance on non-operating income suggest potential challenges ahead. The stock is currently rated as a 'Hold', indicating that while there are positive aspects, caution may be warranted.

Read More

How has been the historical performance of Murae Organisor?

25-Aug-2025

Murae Organisor has shown significant growth in net sales, increasing from 55.11 Cr in March 2020 to 854.82 Cr in March 2025, alongside improvements in profitability metrics, despite challenges in cash flow management. The company's equity capital rose substantially, reflecting a strong capital base during this recovery phase.

Answer:<BR>The historical performance of Murae Organisor shows significant fluctuations in its financial metrics over the years, particularly from March 2019 to March 2025.<BR><BR>Breakdown:<BR>Murae Organisor's net sales have dramatically increased from 55.11 Cr in March 2020 to 854.82 Cr in March 2025, indicating a substantial growth trajectory. However, total operating income followed a similar pattern, rising from 50.70 Cr in March 2019 to 854.82 Cr in March 2025. The company has maintained a consistent zero in raw material costs and other operating income throughout this period. The total expenditure, excluding depreciation, has also seen a rise, from 47.40 Cr in March 2019 to 844.79 Cr in March 2025. Operating profit (PBDIT) has fluctuated, with a notable recovery to 10.03 Cr in March 2025 after experiencing losses in previous years. Profit before tax has similarly improved to 10.03 Cr in March 2025, up from just 0.07 Cr in March 2024. Profit after tax has also shown a positive trend, reaching 7.52 Cr in March 2025 compared to only 0.05 Cr in March 2024. The company's equity capital has increased significantly from 0.31 Cr in March 2019 to 185.90 Cr in March 2025, reflecting a strong capital base. On the balance sheet, total liabilities rose from 23.25 Cr in March 2019 to 119.86 Cr in March 2024, while total assets mirrored this increase, reaching 119.86 Cr in March 2024. Cash flow from operating activities has been negative in recent years, with a notable outflow of 15.00 Cr in March 2024, although financing activities provided a net inflow of 28.00 Cr in the same period. Overall, Murae Organisor's financial performance indicates a recovery and growth phase, particularly in sales and profitability metrics, despite challenges in cash flow management.

Read More

Should I buy, sell or hold Murae Organisor?

26-Aug-2025

Why is Murae Organisor falling/rising?

04-Dec-2025

As of 04-Dec, Murae Organisor Ltd's stock price is at 0.27, unchanged from the previous day, with significant declines of 86.96% year-to-date and 87.21% over the past year. Despite reporting strong growth in net profit and sales, the company's weak financial health and bearish stock performance indicate ongoing challenges.

As of 04-Dec, Murae Organisor Ltd's stock price is currently at 0.27, showing no change from the previous day. The stock has experienced significant declines over various time periods, with a year-to-date drop of 86.96% and a one-year decline of 87.21%. This downward trend is further emphasized by its performance against the benchmark Sensex, which has gained 9.12% year-to-date.<BR><BR>Today, the stock hit a new 52-week low of Rs.0.26 and underperformed its sector by 0.29%. It is trading below all key moving averages, indicating a bearish trend. Despite a rise in investor participation, with delivery volume increasing by 7.05% compared to the five-day average, the overall sentiment remains negative.<BR><BR>While the company has reported impressive growth in net profit and sales, with net profit increasing by 161.05% and net sales growing at an extraordinary rate, these positive results are overshadowed by weak long-term fundamentals. The average return on equity (ROE) is 0%, and the company has a high debt-to-EBITDA ratio of 8.43 times, indicating a low ability to service its debt. This combination of weak financial health and significant stock price declines suggests that Murae Organisor Ltd is currently facing challenges that are contributing to its falling stock price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 8.43 times
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 55 Cr (Small Cap)

stock-summary
P/E

4.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.80

stock-summary
Return on Equity

7.29%

stock-summary
Price to Book

0.26

Revenue and Profits:
Net Sales:
4 Cr
(Quarterly Results - Jun 2025)
Net Profit:
7 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-64.47%
0%
-64.47%
6 Months
-86.76%
0%
-86.76%
1 Year
-87.21%
0%
-87.21%
2 Years
-72.64%
0%
-72.64%
3 Years
-87.59%
0%
-87.59%
4 Years
-97.79%
0%
-97.79%
5 Years
-96.27%
0%
-96.27%

Murae Organisor for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
Announcements stock-summary

Announcement under Regulation 30 (LODR)-Meeting Updates

02-Oct-2025 | Source : BSE

Intimation of adjournment of the AGM due to Lack of Quorum

Intimation Of Adjournment Of The 13Th Annual General Meeting Of The Company Due To Lack Of Quorum

02-Oct-2025 | Source : BSE

Intimation of Adjournment of the 13th Annual General Meeting of the Company due to lack of Quorum

Board Meeting Intimation for Intimation Of Board Meeting Of The Company Scheduled To Be Held On 11Th October 2025

16-Sep-2025 | Source : BSE

Murae Organisor Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/10/2025 inter alia to consider and approve Intimation of Board meeting of the company scheduled to be held on 11th October 2025

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

Murae Organisor Ltd has announced 1:2 stock split, ex-date: 11 Jun 25

stock-summary
BONUS

Murae Organisor Ltd has announced 1:1 bonus issue, ex-date: 09 Aug 21

stock-summary
RIGHTS

Murae Organisor Ltd has announced 1:3 rights issue, ex-date: 19 Dec 24

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
144.61%
EBIT Growth (5y)
33.51%
EBIT to Interest (avg)
0.36
Debt to EBITDA (avg)
29.23
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.55
Tax Ratio
24.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
-12.74%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
4
Industry P/E
34
Price to Book Value
0.26
EV to EBIT
19.75
EV to EBITDA
19.75
EV to Capital Employed
0.59
EV to Sales
0.26
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.36%
ROE (Latest)
7.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

None

Highest Public shareholder

Ifl Enterprises Limited (6.38%)

Individual Investors Holdings

75.04%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -99.23% vs 83.43% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 161.05% vs -28.93% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.99",
          "val2": "515.53",
          "chgp": "-99.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.94",
          "val2": "3.89",
          "chgp": "-75.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.44",
          "val2": "2.85",
          "chgp": "161.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.56%",
          "val2": "0.75%",
          "chgp": "22.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2024 is 2,621.50% vs -81.21% in Sep 2023",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2024 is 157.39% vs -387.50% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "58.24",
          "val2": "2.14",
          "chgp": "2,621.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.88",
          "val2": "-1.61",
          "chgp": "154.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.27",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.66",
          "val2": "-1.15",
          "chgp": "157.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "1.51%",
          "val2": "-75.23%",
          "chgp": "76.74%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 13,257.87% vs -79.78% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 520.72% vs -162.71% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "339.29",
          "val2": "2.54",
          "chgp": "13,257.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.14",
          "val2": "-1.56",
          "chgp": "493.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.27",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.67",
          "val2": "-1.11",
          "chgp": "520.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "1.81%",
          "val2": "-61.42%",
          "chgp": "63.23%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 33,554.33% vs -81.97% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 14,940.00% vs -97.47% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "854.82",
          "val2": "2.54",
          "chgp": "33,554.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "10.03",
          "val2": "-1.13",
          "chgp": "987.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.26",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.52",
          "val2": "0.05",
          "chgp": "14,940.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "1.17%",
          "val2": "-44.49%",
          "chgp": "45.66%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
3.99
515.53
-99.23%
Operating Profit (PBDIT) excl Other Income
0.94
3.89
-75.84%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Standalone Net Profit
7.44
2.85
161.05%
Operating Profit Margin (Excl OI)
23.56%
0.75%
22.81%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -99.23% vs 83.43% in Mar 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Jun 2025 is 161.05% vs -28.93% in Mar 2025

Half Yearly Results Snapshot (Standalone) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
58.24
2.14
2,621.50%
Operating Profit (PBDIT) excl Other Income
0.88
-1.61
154.66%
Interest
0.00
0.27
-100.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.66
-1.15
157.39%
Operating Profit Margin (Excl OI)
1.51%
-75.23%
76.74%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2024 is 2,621.50% vs -81.21% in Sep 2023

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2024 is 157.39% vs -387.50% in Sep 2023

Nine Monthly Results Snapshot (Standalone) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
339.29
2.54
13,257.87%
Operating Profit (PBDIT) excl Other Income
6.14
-1.56
493.59%
Interest
0.00
0.27
-100.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
4.67
-1.11
520.72%
Operating Profit Margin (Excl OI)
1.81%
-61.42%
63.23%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 13,257.87% vs -79.78% in Dec 2023

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2024 is 520.72% vs -162.71% in Dec 2023

Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
854.82
2.54
33,554.33%
Operating Profit (PBDIT) excl Other Income
10.03
-1.13
987.61%
Interest
0.00
0.26
-100.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
7.52
0.05
14,940.00%
Operating Profit Margin (Excl OI)
1.17%
-44.49%
45.66%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 33,554.33% vs -81.97% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is 14,940.00% vs -97.47% in Mar 2024

stock-summaryCompany CV
About Murae Organisor Ltd stock-summary
stock-summary
Murae Organisor Ltd
Small Cap
Pharmaceuticals & Biotechnology
Murae Organisor Limited was originally incorporated as "Earum Pharmaceuticals Private Limited" on July 26, 2012 with the Registrar of Companies, Gujarat, Dadra and Nagar Havelli. Further, Company was converted into a Public Limited and the name of Company was changed to "Earum Pharmaceuticals Limited" vide a fresh Certificate of Incorporation dated January 23, 2019 issued by the Registrar of Companies, Ahmedabad.
Company Coordinates stock-summary
Icon
No Company Details Available